Corrigendum to “Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells” [Biomed. Pharmacother. 131 (2020) 110788]
Jinar Rostami,
Maria Jäntti,
Hengjing Cui,
Maiju K. Rinne,
Jyrki P. Kukkonen,
Anna Falk,
Anna Erlandsson,
Timo Myöhänen
Affiliations
Jinar Rostami
Molecular Geriatrics, Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden
Maria Jäntti
Division of Pharmacology and Pharmacotherapy/Drug Research Program, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014, University of Helsinki, Finland
Hengjing Cui
Division of Pharmacology and Pharmacotherapy/Drug Research Program, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014, University of Helsinki, Finland
Maiju K. Rinne
Division of Pharmaceutical Chemistry and Technology/Drug Research Program, Faculty of Pharmacy, P.O. Box 56, 00014, University of Helsinki, Finland
Jyrki P. Kukkonen
Department of Pharmacology, Institute of Biomedicine, Faculty of Medicine, P.O. Box 63, 00014, University of Helsinki, Finland
Anna Falk
Department of Neuroscience, Karolinska Institutet, Stockholm 17177, Sweden
Anna Erlandsson
Molecular Geriatrics, Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden
Timo Myöhänen
Division of Pharmacology and Pharmacotherapy/Drug Research Program, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014, University of Helsinki, Finland; Integrative Physiology and Pharmacology Unit, Institute of Biomedicine, 20014 Turun yliopisto, University of Turku, Finland; Corresponding author at: Division of Pharmacology and Pharmacotherapy/Drug Research Program, Viikinkaari 5E, P.O. Box 56, 00014 University of Helsinki, Finland.
